Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 15/20 | 0.36 |
| ▸ | NOS2 | P35228 | 10/20 | 0.36 |
| ▸ | NOS3 | P29474 | 8/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1157243 | 0.78 | NOS1 (0.53) | TSHRNOS1NOS2NOS3 | |
| SCHEMBL14028969 | 0.78 | NOS1 (0.36) | NOS1NOS2NOS3CHRNA7 | |
| SCHEMBL11982706 | 0.78 | SIGMAR1 (0.47) | NOS1NOS2 | |
| SCHEMBL13715502 | 0.78 | NOS1 (0.41) | NOS1NOS2NOS3CHRNA7 | |
| SCHEMBL8439706 | 0.78 | TRPA1 (0.42) | TSHRNOS1NOS2NOS3CHRNA7 | |
| SCHEMBL10134884 | 0.78 | NOS1 (0.58) | NOS1NOS2NOS3PNMT | |
| SCHEMBL842651 | 0.78 | MAPK1 (0.46) | TSHRNOS1NOS2NOS3PNMT | |
| SCHEMBL657613 | 0.77 | CALM1 (0.50) | — | |
| SCHEMBL9612169 | 0.76 | NOS1 (0.33) | NOS1NOS2NOS3 | |
| SCHEMBL12123447 | 0.76 | CTBP2 (0.40) | NOS1NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103917527-B | Dibasic 5 fluoropyrimidine | 拜耳知识产权有限责任公司 | 2017-05-31 | — | — | CN | disclosed |
| EP-2516405-B1 | 4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY | VIROSTATICS S R L (IT) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014170833-A2 | COLORED CHARGED SILSESQUIOXANES | BASF SE (DE) | 2014-10-23 | — | — | WO | disclosed |
| EP-1960370-B1 | PYRIDIAZINONE DERIVATIVES FOR TUMOUR TREATMENT | MERCK PATENT GMBH (DE) | 2011-10-05 | — | — | EP | disclosed |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S | 2004-05-20 | — | — | US | disclosed |
| US-3954973-A | ALKYL HALIDES | AMERICAN CYANAMID COMPANY (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | TSHR 1559/4885NOS1 1814/4885NOS2 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.